Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Reported Basic Consolidated EPS Of $-5.2884 For Period Ended 2015-12-31

0

The annual basic consolidated EPS for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) for the period ended 2015-12-31 was $-5.2884. On quarterly basis, the basic consolidated EPS reading for the quarter ended 2015-12-31 was $-5.2884.

EPS from continuing operations

Coming to basic EPS from continuing operations, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) reported $-5.4022 for the annual period ended 2015-12-31. Quarterly basic EPS from continuing operations for the three-month period ended 2015-12-31 stood at $-5.4022.

EPS contribution from parent

For the annual period ended 2015-12-31, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) received basic EPS of $-5.2884 from its parent company. On quarterly basis, basic EPS contribution from the parent company for the period ended 2015-12-31 was $-5.2884.

Basic net EPS

For the annual period ended 2015-12-31, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) reported basic net EPS of $-5.4022. On quarterly basis, the company’s basic net EPS for the three-month period ended 2015-12-31 stood at $-5.4022.

Consolidated diluted EPS

The annual consolidated diluted EPS reading for the period ended 2015-12-31 stood at $-5.2884. For the quarter ended 2015-12-31, consolidated diluted EPS was $-5.2884.

Basic diluted EPS

On annual basis, diluted EPS reading from continuing operation was $-5.4022 for the period ended 2015-12-31. Diluted EPS from continuing operations for the quarter ended 2015-12-31 was $-5.4022.

Net diluted EPS

Net diluted EPS reading for the annual period ended 2015-12-31 was $-5.4022. For the quarterly period ended 2015-12-31, net diluted EPS was $-5.4022.

Diluted EPS from parent

From the parent company, Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) received diluted EPS of $-5.2884 for the annual period ended 2015-12-31. On quarterly basis, diluted EPS contribution from the parent for the quarter ended 2015-12-31 was $-5.2884.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted net basic EPS reading of $-5.4022 for the annual period ended 2015-12-31. For the quarter, basic net EPS of $-5.4022 was for the quarter ended 2015-12-31.

Net diluted EPS for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) for the annual period ended 2015-12-31 was $-5.4022. The company also reported net diluted EPS reading of $-5.4022 for the quarter ended 2015-12-31.

The annual average basic shares outstanding for the period ended 2015-12-31 is 2.712 while for the quarter ended 2015-12-31 is 2.712.

The diluted shares outstanding for the fiscal year ended is 2015-12-31 is 2.712 while for the quarter ended 2015-12-31 is 2.712.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 19 times, 1 visits today)